120 related articles for article (PubMed ID: 3733375)
1. Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors.
Pratt CB; Sinkule JA; Etcubanas E; Douglass EC; Crom DB; Choi K; Avery L
Invest New Drugs; 1986; 4(2):149-53. PubMed ID: 3733375
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
Weiss GR; Hersh M; Kuhn JG; Ludden TM; von Hoff DD; Kisner DL; Pirtle TE
Cancer Chemother Pharmacol; 1985; 15(2):144-8. PubMed ID: 4017163
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
[TBL] [Abstract][Full Text] [Related]
5. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of topotecan for pediatric patients with malignant solid tumors.
Pratt CB; Stewart C; Santana VM; Bowman L; Furman W; Ochs J; Marina N; Kuttesch JF; Heideman R; Sandlund JT
J Clin Oncol; 1994 Mar; 12(3):539-43. PubMed ID: 8120551
[TBL] [Abstract][Full Text] [Related]
7. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL).
Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S
Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.
Lu K; Savaraj N; Yap BS; Feun LG; Umsawasdi T; Loo TL
Cancer Chemother Pharmacol; 1986; 16(2):156-9. PubMed ID: 3948302
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of bisantrene in childhood cancer: a report from the Childrens Cancer Study Group.
Movassaghi N; Krivit WA; Krailo MD; Hammond GD
Med Pediatr Oncol; 1988; 16(5):333-6. PubMed ID: 3054454
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
Coates AS; Bishop J; Mann GJ; Raghavan D
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):97-100. PubMed ID: 3754214
[TBL] [Abstract][Full Text] [Related]
12. Anaphylactoid reactions associated with bisantrene infusions.
Myers JW; Von Hoff DD; Kuhn JG; Osborne CK; Sandbach JF; Pocelinko R
Invest New Drugs; 1983; 1(1):85-8. PubMed ID: 6678858
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
16. Bisantrene in relapsed and refractory acute myelogenous leukemia.
Spadea A; Petti MC; Aloespiriti MA; Avvisati G; De Gregoris C; Fazi P; Latagliata R; Amadori S; Mandelli F
Leuk Lymphoma; 1993 Feb; 9(3):217-20. PubMed ID: 8471980
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.
Heideman RL; Cole DE; Balis F; Sato J; Reaman GH; Packer RJ; Singher LJ; Ettinger LJ; Gillespie A; Sam J
Cancer Res; 1989 Feb; 49(3):736-41. PubMed ID: 2491958
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
